ZSNeo-DC1.1
/ Zhongsheng Kangyuan Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
August 07, 2025
Phase I clinical trial of personalized dendritic cell injection ZSNeo-DC1.1 in the treatment of malignant solid tumors
(ChiCTR)
- P1 | N=12 | Completed | Sponsor: Chinese People's Liberation Army General Hospital; Zhongsheng Kangyuan Biotechnology (Beijing) Co., LTD
New P1 trial • Solid Tumor
February 12, 2025
ZSKY2023-1002: Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade Gliomas
(clinicaltrials.gov)
- P1 | N=12 | Recruiting | Sponsor: Beijing Tiantan Hospital | Trial completion date: Feb 2025 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Jun 2025
Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Malignant Glioma • Oncology • Solid Tumor
February 12, 2024
Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade Gliomas
(clinicaltrials.gov)
- P1 | N=12 | Recruiting | Sponsor: Beijing Tiantan Hospital
New P1 trial • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor
1 to 3
Of
3
Go to page
1